| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T283 |
0-108 |
Sentence |
denotes |
There are circumstances where binding to FcγR is unnecessary or undesirable in the MOA of a therapeutic mAb. |
| T284 |
109-446 |
Sentence |
denotes |
Unmodified IgG irrespective of its subclass or intended therapeutic effect has the potential to engage an FcγR which may lead to suboptimal therapeutic performance or to unexpected and catastrophic consequences.57, 59 Clearly reducing or eliminating FcγR interactions, when they are not required for therapeutic effect, may be desirable. |
| T285 |
447-539 |
Sentence |
denotes |
Indeed, this had been addressed by the choice of IgG subclass or by modifying the Fc region. |
| T286 |
540-701 |
Sentence |
denotes |
Indeed, most efforts in Fc engineering mAbs that have translated to an approved drug have focused on the reduction or elimination of FcγR interactions (Table 4). |
